Physician profile
Khaled Nass
NPI 1861495830
$4,133.96
in general payments reported to CMS, 2019-2025
29 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $157 · 2021: $568 · 2022: $869 · 2023: $677 · 2024: $813 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.23 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $528.30 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $486.35 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $484.19 | 2020-2025 | Farxiga |
| Vifor Pharma, INC. | $382.32 | 2019-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $367.49 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $263.36 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $232.76 | 2021-2025 | |
| Daiichi Sankyo INC. | $214.78 | 2019-2023 | Injectafer |
| Travere Therapeutics, INC. | $154.56 | 2020-2025 | |
| Outset Medical INC | $109.54 | 2022 | |
| Mallinckrodt Enterprises LLC | $104.02 | 2019 | |
| Glaxosmithkline, LLC. | $95.24 | 2022-2024 | Benlysta |
| Akebia Therapeutics INC | $94.22 | 2020-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $79.17 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $76.67 | 2023-2024 | Tarpeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $70.27 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $67.58 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $49.62 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $46.64 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $42.21 | 2022-2025 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $33.16 | 2023-2025 | Amvuttra, Onpattro |
| Cormedix INC. | $25.49 | 2024 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.37 | 2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $21.15 | 2025 | Empaveli |
| Amicus Therapeutics, INC. | $20.24 | 2020 | |
| Genzyme Corporation | $17.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.08 | 2020 | |
| Ardelyx, INC. | $13.82 | 2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Nass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.